The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New Jersey ...

Biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) filed a patent infringement lawsuit against Merck & Co., Inc. (MRK) on Thursday, alleging that the latter uses Halozyme's patented MDASE ...

The Food and Drug Administration is due to make an approval decision on injectable Keytruda by mid-September in a move that could bolster Merck's biggest franchise and downtrodden Merck stock.

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in ...

SAN DIEGO, April 24, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (Halozyme), a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, today ...

Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab). This version, which will be marketed as ...

Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...

Subcutaneous Keytruda plus chemotherapy met pharmacokinetic endpoints, showing noninferiority to the intravenous formulation in metastatic NSCLC treatment. The subcutaneous formulation, administered ...

Keytruda Qlex is a new form of pembrolizumab, a cancer-fighting lab-made antibody that helps your immune system find and attack cancer cells. Unlike the original 30-minute intravenous (IV) drip, the ...

(RTTNews) - Merck & Co Inc. (MRK) Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in adults with non-small cell lung cancer (NSCLC) met its ...